In a recent elegant study, 62 postmenopausal women with normal glucose tolerance (normal) were compared with 33 postmenopausal women with impaired glucose tolerance (IGT) and 18 women with type 2 diabetes (T2D) [1]. Women were further divided according to the status of the visceral abdominal fat. The contribution of glucose tolerance status and intra-abdominal fat… Read More
Breast cancer risk and the interval between menopause and starting HT
In the January issue of the [i]Journal of the National Cancer Institute[/i], Valerie Beral and co-workers report an update on the association between use of hormone therapy (HT) and breast cancer risk in the Million Women Study cohort [1]. After extended follow-up, more postmenopausal women (1,129,025 vs. 828,923) and more incident breast cancers (15,759 vs.… Read More
Physiological changes in scalp, facial and body hair after the menopause
In a new and quite unique study, Ali and Wojnarowska [1] aim to assess the subjective experience of changes in scalp, facial and body hair in a large cohort of healthy postmenopausal females of northern European ethnicity. It is the first epidemiological study of its kind in more than 20 years. The previous three largest… Read More
Cigarette smoking and the incidence of breast cancer
A recent paper, published by Xue and colleagues in the [i]Archives of Internal Medicine[/i], looked at the association between active or passive smoking and breast cancer risk among the Nurses’ Health Study cohort [1]. The Nurses’ Health Study is a prospective cohort study of 111,140 participants followed up from 1976 to 2006 for active smoking… Read More
Health outcomes in postmenopausal women with prior hysterectomy after stopping CEE therapy
LaCroix and colleagues [1] recently reported health outcomes after stopping therapy among postmenopausal women randomized to conjugated equine estrogens (CEE) in the estrogen-only arm of the Women’s Health Initiative. A total of 7645 women (78% of the original cohort) gave consent to be included in this follow-up over a mean duration of 10.7 years. Post-intervention… Read More
Overweight and health outcomes
There has been a continuous interest in the consequences of excessive weight on health outcomes, mainly because of the fact that the world’s population is becoming heavier. The World Health Organization estimates that more than 1 billion people are overweight, with 300 million meeting the criteria for obesity. A recent review on this issue [1]… Read More
Vaginal pH-balanced gel for the control of atrophic vaginitis in breast cancer survivors
A recently published randomized, controlled trial [1] has examined the effects of a topical vaginal pH-balanced gel on symptoms of atrophic vaginitis amongst women who have been treated for breast cancer. Ninety-eight women were enrolled in the study and 86 completed the trial. All participants were postmenopausal prior to the diagnosis of their breast cancer.… Read More
Estrogen therapy, blood pressure and renal function
Fung and colleagues have recently reported on a cross-sectional study, followed by a prospective analysis, on the effect of continuous postmenopausal estrogen therapy over a period of 10 years on blood pressure, microalbuminuria and renal function [1]. A total of 1044 postmenopausal women (mean age 72 years) were evaluated cross-sectionally between 1992 and 1996. These… Read More
Endogenous androgens and effects on body fat and insulin resistance
In a recently published study, Casson and colleagues evaluated endogenous serum androgens and sex hormone binding globulin (SHBG) in 29 normal, non-obese, naturally occurring postmenopausal women whose ages ranged from 52 to 70 years [1]. Correlations were then evaluated between serum androgens and SHBG and insulin sensitivity, whole-body fat and lean body mass, visceral/abdominal fat… Read More
Effect of hormone therapy on lean body mass, falls and fractures
Bea and colleagues [1] have recently reported on results from a Women’s Health Initiative (WHI)-based sub-study that investigated possible effects of hormone therapy (HT) on lean mass, incidence of falls and fractures. The mean age at baseline was 63 years, and the mean time since menopause ranged from 13.3 to 22.5 years. Women were randomly… Read More